Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults

Eur J Haematol. 2021 Sep;107(3):374-376. doi: 10.1111/ejh.13669. Epub 2021 May 30.

Authors

Takaaki Konuma¹, Maki Monna-Oiwa¹, Masamichi Isobe¹, Motohito Okabe¹, Satoshi Takahashi¹, Arinobu Tojo¹

Affiliation

¹ Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

PMID: 34028079
DOI: 10.1111/ejh.13669

No abstract available

Keywords: busulfan; cord blood transplantation; cyclophosphamide; fludarabine; hematopoietic cell transplantation; myeloablative conditioning.

Publication types

Letter

MeSH terms

Adult
Blood Platelets / immunology
Blood Platelets / pathology
Busulfan / therapeutic use*
Cord Blood Stem Cell Transplantation / methods*
Cyclophosphamide / therapeutic use*
Drug Administration Schedule
Female
Graft vs Host Disease / diagnosis
Graft vs Host Disease / immunology
Graft vs Host Disease / pathology
Hematologic Neoplasms / immunology
Hematologic Neoplasms / mortality
Hematologic Neoplasms / pathology
Hematologic Neoplasms / therapy*
Humans
Male
Middle Aged
Myeloablative Agonists / therapeutic use*
Neutrophils / immunology
Neutrophils / pathology
Retrospective Studies
Survival Analysis
Transplantation Conditioning / methods
Vidarabine / analogs & derivatives*
Vidarabine / therapeutic use

Substances

Myeloablative Agonists
Cyclophosphamide
Vidarabine
Busulfan
fludarabine